СПИСОК ЛИТЕРАТУРЫ

Поставить закладку

1. Абдулкадыров К.М. Блинов М.Н., Щербакова Е.Г., Сорокин Е.М., Шляпочникова Г.П., Куравлева В.В., Егорова В.А., Беляева Л.В., Рогалева Е.Ю., Дифференциальная диагностика идиопатического миелофиброза и хронического миелолейкоза. 1985, Ленинград. 43с.
2. Абдулкадыров К.М. Ломайа Е.Г., Шуваев В. А., Абдулкадырова А.С., Удальева В.Ю., Усачева Е.И., Шихбабаева Д.И., Мачюлайтене Е.Р., Зотова И.И., Позняк Е.И., Иванова М.О., Карягина Е.В., Ильина Н.В., Шнейдер Т.В., Романова Е.Г., Саламатова Е.И., Лазорко Н.С., Мартынкевич И.С., Зарицкий А.Ю., Оценка выживаемости, достижения молекулярного, цитогенетического ответов у пациентов с хроническим миелолейкозом в хронической фазе, получающих терапию Иматинибом: данные девятилетнего популяционного наблюдения больных хроническим миелолейкозом Санкт-Петербурга и Ленинградской области. Вестник гематологии, 2010. 5(2): С. 5.
3. Абдулкадыров К.М. Туркина А.Г., Хорошко Н.Д., Рекомендации по диагностике и терапии хронического миелолейкоза. 2013, Санкт-Петербург, Москва. 80 с.
4. АбдулкадыровК.М., Клиническая гематология : справочник. 2006, Санкт- Петербург: Питер : Питер Принт. 748 с.
5. Аксенова Е.В. Крутов А.А., Солдатова И.Н., Челышева Е.Ю., Туркина А.Г., Хорошко Н.Д., Мисюрин А.В., Молекулярный мониторинг у пациентов с хроническим миелолейкозом: корреляция с цитогенетическим ответом, прогностическое значение, оценка ответа на терапию. Клиническая онкогематология, 2010. 3(2): С. 151-159.
6. Воробьев А.И. Абдулкадыров К.М., Хорошко Н.Д., Диагностика и терапия хронического миелолейкоза. 2011, Москва. 53 с.
7. Воробьев А.И., Руководство по гематологии. М. Ньюдиамед 2003. 3: С. 9-15.
8. Голенков А.К. Высоцкая Л.Л., Трифонова Е.В., Эффективность программы лечения хронического миелолейкоза гливеком в широкой клинической практике. Альманах клинической медицины МОНИКИ, 2008(18): С. 9-13.
9. Домрачева Е.В. Аксенова Е.А., Роль цитогенетических исследований при лечении хронического миелолейкоза ингибиторами тирозинкиназ. Гематология и трансфузиология, 2007. 52(2): С. 25-28.
10. Зарицкий А.Ю. Виноградова О.Ю., Лория С.С., и др., Факторы прогноза при терапии иматиниба мезилатом у больных в хронической фазе Рh-позитивного хронического миелолейкоза: данные многоцентрового нерандомизированного исследования в России. Терапевтический архив, 2007(8): С. 17-22.
11. Мартынкевич И.С. Мартыненко Л.С., Иванова М.П. и др., Дополнительные хромосомные аберрации у больных хроническим миелолейкозом. Гематология и трансфузиология, 2007. 52(2): С. 35-40.
12. Мисюрин А.В. Аксенова Е.В., Крутов А.А. и соавт., Молекулярная диагностика хронического миелолейкоза. Гематология и трансфузиология 2007. 52(2): С. 3540.
13. Оксфордский центр доказательной медицины. Уровни доказательности (Май 2001). Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998.
14. Стахина О.В. Туркина А.Г., Гусарова Г. А., Виноградова О.Ю., Захарова Е.С., Абакумов Е.М, Челышева Е.Ю., Колошейнова Т.И., Г орячева С.Р., Колосова Л.Ю., Домрачева Е.В., А.В.Захарова, Дяченко Л.В., Куликов С.М., Ковалева Л.Г., Хорошко Н.Д. , Отдаленные результаты выживаемости больных в поздней хронической фазе Ph+ хронического миелолейкоза при лечении иматиниб мезилатом (Гливек®). Вестник гематологии, 2009. 5(2): С. 42.
15. Туркина А.Г. Хорошко Н.Д. и соавт., Практические рекомендации по лечению больных хроническим миелолейкозом. М. Тверь: Триада, 2005. 43 с.
16. Туркина А.Г. Хельман Р., Поспелова Т.И., Виноградова О.Ю., Ионова Т.И., «Практические аспекты терапии хронического миелолейкоза в хронической фазе». Материалы выступлений Всероссийского конгресса гематологов, Москва, 3 июля 2012 г. Онкогематология, 2012. 2012(3): С. 8.
17. Челышева Е.Ю. Т.А.Г., Мисюрин А.В., Захарова А.В., Раннее выявление цитогенетического рецидива при динамическом исследовании уровня BCR-ABL транскрипта у больного хроническим миелолейкозом. Гематология и трансфузиология 2007. 52(2): С. 50-51.
18. Шуваев. В. А. А.А.С., Мартынкевич И.С., Удальева В.Ю., Усачева Е.И., Зотова И.И., Шихбабаева Д.И., Цыбакова Н.Ю., Москаленко М.В., Аксенова В.Ю., Мартыненко Л.С., Иванова М.П., Петрова Е.В., Иванова М.О., Мачюлайтене Е.Р., Позняк Е.И., Карягина Е.В., Ильина Н.В., Лазорко Н.С., Ломаиа Е.Г., Зарицкий А.Ю., Абдулкадыров К.М. Опыт лечения хронического миелолейкоза в Санкт-Петербурге. Вестник Гематологии, 2011. 7(1): С. 43.
19. Baccarani M., J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R.T. Silver, J. Goldman, and R. Hehlmann, Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009. 27(35): p. 6041-6051.
20. Baccarani M., S. Pileri, J.-L. Steegmann, M. Muller, S. Soverini, M. Dreyling, and o.b.o.t.E.G.W. Group, Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment andfollow-up. Annals of Oncology, 2012. 23(suppl 7): p. vii72-vii77.
21. Baccarani M., G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, and R. Hehlmann, Evolving concepts in the management of chronic myeloid leukemia: recommendations _ from an expert panel on behalf of the European LeukemiaNet. Blood, 2006. 108(6): p. 1809-1820.
22. Berveiller P., A. Andreoli, O. Mir, O. Anselem, A.-L. Delezoide, H. Sauvageon, N. Chapuis, and V. Tsatsaris, A dramatic_ fetal outcome_ following transplacental transfer of dasatinib. Anti-Cancer Drugs, 2012. 23(7): p. 754-757 10.1097/CAD.0b013e328352a8fe.
23. Branford S., R. Lawrence, A. Grigg, J.F. Seymour, A. Schwarer, C. Arthur, Z. Rudzki, and T. Hughes, Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. ASH Annual Meeting Abstracts, 2008. 112(11): p. 2113-.
24. Breccia M., L. Cannella, E. Montefusco, A. Frustaci, M. Pacilli, and G. Alimena, Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. Leukemia research, 2008. 32(3): p. 519-520.
25. Common, Terminology Criteria for Adverse Events v4.0 (CTCAE). Publish Date: May 28, 2009, NIH Publication No. 09-5410.
26. Cortes J., Natural history and staging of chronic myelogenous leukemia. Hematology/oncology clinics of North America, 2004. 18(3): p. 569-584.
27. Cortes J., P. Rousselot, D.-W. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, O. Ottmann, N. Shah, P. Erben, S. Branford, P. Agarwal, A. Gollerkeri, and M. Baccarani, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007. 109(8): p. 32073213.
28. de Padua Silva L., J. Cortes, E. Jabbour, S. Giralt, P. Kebriaei, S. O'Brien, A. Alousi, M. Qazilbash, G. Rondon, F. Ravandi, R. Ribeiro, C. Hosing, H. Kantarjian, R. Champlin, and M. De Lima, Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. ASH Annual Meeting Abstracts, 2008. 112(11): p. 2154-.
29. DeiningerM., S.G. O'Brien, F. Guilhot, J.M. Goldman, A. Hochhaus, T.P. Hughes, J.P. Radich, A.K. Hatfield, M. Mone, J. Filian, J. Reynolds, I. Gathmann, R.A. Larson, and B.J. Druker, International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk. for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts, 2009. 114(22): p. 1126-.
30. Giles F.J., J.E. Cortes, H.M. Kantarjian, and S.M. O'Brien, Accelerated and blastic phases of chronic myelogenous leukemia. Hematology/oncology clinics of North America, 2004. 18(3): p. 753-774.
31. Giles F.J., G. Rosti, P. Beris, R.E. Clark, P. le Coutre, F.-X. Mahon, J.-L. Steegmann, P. Valent, and G. Saglio, Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology, 2010. 3(6): p. 665-673.
32. Gratwohl A., J. Hermans, J.M. Goldman, W. Arcese, E. Carreras, A. Devergie, F. Frassoni, G. Gahrton, H.J. Kolb, D. Niederwieser, T. Ruutu, J.P. Vernant, T. de Witte, and J. Apperley, Risk assessment _ for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. The Lancet, 1998. 352(9134): p. 10871092.
33. Griffin J.D. and E.L. Weisberg, Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia. ASH Annual Meeting Abstracts, 2005. 106(11): p. 694-.
34. Guidelines N. Version 4.2013 Chronic Myelogenous Leukemia.
35. Guilhot F., J. Apperley, D.-W. Kim, E.O. Bullorsky, M. Baccarani, G.J. Roboz, S. Amadori, C.A. de Souza, J.H. Lipton, A. Hochhaus, D. Heim, R.A. Larson, S. Branford, M.C. Muller, P. Agarwal, A. Gollerkeri, and M. Talpaz, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007. 109(10): p. 4143-4150.
36. Guilhot F., J.F. Apperley, N. Shah, D.W. Kim, A. Grigg, S. Cheng, M. Iyer, and J. Cortes, A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 'START-A' Study. ASH Annual Meeting Abstracts, 2005. 106(11): p. 39-.
37. Hasford J., M. Baccarani, V. Hoffmann, J. Guilhot, S. Saussele, G. Rosti, F. Guilhot, K. Porkka, G. Ossenkoppele, D. Lindoerfer, B. Simonsson, M. Pfirrmann, and R. Hehlmann, Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood, 2011. 118(3): p. 686-692.
38. Hochhaus A., H.M. Kantarjian, M. Baccarani, J.H. Lipton, J.F. Apperley, B.J. Druker, T. Facon, S.L. Goldberg, F. Cervantes, D. Niederwieser, R.T. Silver, R.M. Stone, T.P. Hughes, M.C. Muller, R. Ezzeddine, A.M. Countouriotis, and N.P. Shah, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007. 109(6): p. 2303-2309.
39. Hochhaus A S.N., Cortes JE, Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. Program and abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, Illinois. Abstract 6504., 2012.
40. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm.
41. Hughes T., M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N.C.P. Cross, B.J. Druker, J. Gabert, D. Grimwade, R. Hehlmann, S. Kamel-Reid, J.H. Lipton, J. Longtine, G. Martinelli, G. Saglio, S. Soverini, W. Stock, and J.M. Goldman, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations. for harmonizing current methodology . for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006. 108(1): p. 28-37.
42. Hughes T.P., A. Hochhaus, G. Saglio, D.-W. Kim, S. Jootar, P.D.l. Coutre, J. Reiffers, R. Pasquini, C. Lobo, R.E. Clark, N.J. Gallagher, A. Hoenekopp, A. Haque, R.A. Larson, and H.M. Kantarjian, ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). ASH Annual Meeting Abstracts, 2010. 116(21): p. 207-.
43. Jabbour E., J. Cortes, F. Giles, S. O'Brien, and H. Kantarijan, Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs, 2007. 10(7): p. 468-79.
44. Kantarjian H.M. K.D.-W., Issaragrisil S., Clark R.E., Reiffers J., Enestnd4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Program and abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, Illinois. Abstract 1676, 2012.
45. Kantarjian H.M., N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Agarwal, M.S. Undurraga, J. Wang, J.J. Kassack Ipina, D.-W. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, J.H. Milone, F.E. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, M.B. Bradley-Garelik, C. Zhu, and A. Hochhaus, Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2011.
46. Kantarjian H.M., M. Talpaz, S. O'Brien, D. Jones, F. Giles, G. Garcia-Manero, S. Faderl, F. Ravandi, M.B. Rios, J. Shan, and J. Cortes, Survival benefit with imatinib mesylate versus interferon-a □ based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 2006. 108(6): p. 1835-1840.
47. Krauth M.-T., S. Herndlhofer, M.-T. Schmook, G. Mitterbauer-Hohendanner, E. Schlogl, and P. Valent, Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica, 2011. 96(1): p. 163-166.
48. le Coutre P., O.G. Ottmann, F. Giles, D.-W. Kim, J. Cortes, N. Gattermann, J.F. Apperley, R.A. Larson, E. Abruzzese, S.G. O'Brien, K. Kuliczkowski, A. Hochhaus, F.-X. Mahon, G. Saglio, M. Gobbi, Y.-L. Kwong, M. Baccarani, T. Hughes, G. Martinelli, J.P. Radich, M. Zheng, Y. Shou, and H. Kantarjian, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008. 111(4): p. 1834-1839.
49. le Coutre P.D., A. Turkina, D.-W. Kim, B. Ceglarek, G. Alimena, H.K. Al-Ali, Z. Shen, S. Jootar, G. Smith, C.A. De Souza, P.E. Dorlhiac-Llacer, D.A. Rizzieri, T. Szczudlo, M. Berton, J. Wang, S.-T. Wang, and F.E. Nicolini, Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. ASH Annual Meeting Abstracts, 2009. 114(22): p. 3286-.
50. Mahon F.o.-X., D. R?a, J.l. Guilhot, F.o. Guilhot, F.o. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A.s. Guerci, B. Varet, G. Etienne, J. Reiffers, and P. Rousselot, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission_ for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology, 2010. 11(11): p. 10291035.
51. Marin D., D. Milojkovic, E. Olavarria, J.S. Khorashad, H. de Lavallade, A.G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, J. Pavlu, M. Klammer, J.S. Kaeda, J.M. Goldman, and J.F. Apperley, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood, 2008. 112(12): p. 4437-4444.
52. Mauro M. J. B.M., Cervantes F., Lipton J. H., Matloub Y., Sinha R., Stone R. M., Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). Journal of Clinical Oncology, 2008. 26(15S (May 20 Supplement)): p. 1.
53. O'Brien S.G., F. Guilhot, J.M. Goldman, A. Hochhaus, T.P. Hughes, J.P. Radich, M. Rudoltz, J. Filian, I. Gathmann, B.J. Druker, and R.A. Larson, International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM). ASH Annual Meeting Abstracts, 2008. 112(11): p. 186-.
54. O'Hare T., W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, F. Wang, L.T. Adrian, T. Zhou, W.-S. Huang, Q. Xu, C.A. Metcalf, J.W. Tyner, M.M. Loriaux, A.S. Corbin, S. Wardwell, Y. Ning, J.A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. Snodgrass, L. Commodore, T.K. Sawyer, D.C. Dalgarno, M.W.N. Deininger, B.J. Druker, and T. Clackson, AP24534, a Pan-BCR-ABL Inhibitor. for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer cell, 2009. 16(5): p. 401-412.
55. O'Hare T., D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, J. Mestan, S.W. Cowan-Jacob, F.Y. Lee, M.C. Heinrich, M.W.N. Deininger, and B.J. Druker, In vitro Activity of Bcr-AblInhibitors AMN107 andBMS-354825 against Clinically Relevant Imatinib-Resistant AblKinase Domain Mutants. Cancer Research, 2005. 65(11): p. 4500-4505.
56. Pavlovsky C., I. Giere, V. Lombardi, P. Negri, B. Moiraghi, J. Garcia, M.A. Pavlovsky, M.F.G. Reinoso, R. Bengio, R. Campestri, J. Milone, R. Uriarte, A. Magarinos, L. Martinez, N. Mur, V. Labanca, G. Via, C. Corrado, I. Fernandez, and S. Pavlovsky, Monitoring Minimal Residual Disease by Quantitative PCR in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission. ASH Annual Meeting Abstracts, 2008. 112(11): p. 4272-.
57. Porkka K., P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, L. Eccersley, H. Hjorth-Hansen, M. Hoglund, H. Klamova, H. Knutsen, S. Parikh, E. Raffoux, F. Gruber, F. Brito-Babapulle, H. Dombret, R.F. Duarte, E. Elonen, R. Paquette, C.M. Zwaan, and F.Y.F. Lee, Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 2008. 112(4): p. 1005-1012.
58. Powell B.L., H.J. Khoury, J.H. Lipton, D.A. Rizzieri, D. Williams, and A.R. Turner, Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials). ASH Annual Meeting Abstracts, 2009. 114(22): p. 3295-.
59. Press R.D., Z. Love, A.A. Tronnes, R. Yang, T. Tran, S. Mongoue-Tchokote, M. Mori, M.J. Mauro, M.W. Deininger, and B.J. Druker, BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate □ treated patients with CML. Blood, 2006. 107(11): p. 4250-4256.
60. Pye S.M., J. Cortes, P. Ault, A. Hatfield, H. Kantarjian, R. Pilot, G. Rosti, and J.F. Apperley, The effects of imatinib on pregnancy outcome. Blood, 2008. 111(12): p. 5505-5508.
61. Quintas-Cardama A., X. Han, H. Kantarjian, and J. Cortes, Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood, 2009. 114(2): p. 261-263.
62. Quintas-Cardama A., H. Kantarjian, S. O'Brien, G. Borthakur, J. Bruzzi, R. Munden, and J. Cortes, Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. Journal of Clinical Oncology, 2007. 25(25): p. 3908-3914.
63. Russell M.A., M.W. Carpenter, M.S. Akhtar, T.F. Lagattuta, and M.J. Egorin, Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol, 0000. 27(4): p. 241-243.
64. Saglio G., P.D. LeCoutre, R. Pasquini, S. Jootar, H. Nakamae, I.W. Flinn, A. Hochhaus, T.P. Hughes, R.A. Larson, A. Hoenekopp, N.J. Gallagher, R. Yu, R.E. Blakesley, D.-W. Kim, and H.M. Kantarjian, Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. ASH Annual Meeting Abstracts, 2011. 118(21): p. 452-.
65. Silver R.T., Chronic myeloid leukemia. Hematology/oncology clinics of North America, 2003. 17(5): p. 1159-1173.
66. Sokal J., E. Cox, M. Baccarani, S. Tura, G. Gomez, J. Robertson, C. Tso, T. Braun, B. Clarkson, and F. Cervantes, Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 1984. 63(4): p. 789-799.
67. Soverini S., S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. lacobucci, M. Amabile, E. Abruzzese, E. Orlandi, F. Radaelli, F. Ciccone, M. Tiribelli, R. di Lorenzo, C. Caracciolo, B. Izzo, F. Pane, G. Saglio, M. Baccarani, G. Martinelli, and o.b.o.t.G.W.P.o.C.M. Leukemia, Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research, 2006. 12(24): p. 7374-7379.
68. Soverini S., A. Gnani, S. Colarossi, F. Castagnetti, E. Abruzzese, S. Paolini, S. Merante, E. Orlandi, S. de Matteis, A. Gozzini, I. lacobucci, F. Palandri, G. Gugliotta, C. Papayannidis, A. Poerio, M. Amabile, D. Cilloni, G. Rosti, M. Baccarani, and G. Martinelli, Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 2009. 114(10): p. 2168-2171.
69. Swerdlow S.H. C.E., Hariris N.L. et al., World Health Organization of Tumours of Haematopoietic and Lymphoid Tissues. 2008, Lyon: IARC Press.
70. tablets G.i.m., Imatinib prescribing information. 2007: East Hanover, New Jersey, Novartis Pharmaceuticals Corporation, Revised November.
71. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel S.N.P.A. 2011.
72. Tefferi A. and L. Letendre, Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as. front-line therapy . for chronic myelogenous leukemia. American Journal of Hematology, 2011. 86(7): p. 610-611.
73. Testoni N., G. Marzocchi, S. Luatti, M. Amabile, C. Baldazzi, M. Stacchini, M. Nanni, G. Rege-Cambrin, E. Giugliano, U. Giussani, E. Abruzzese, S. Kerim, M.G. Grimoldi, A. Gozzetti, B. Crescenzi, C. Carcassi, P. Bernasconi, A. Cuneo, F. Albano, G. Fugazza, A. Zaccaria, G. Martinelli, F. Pane, G. Rosti, and M. Baccarani, Chronic myeloid leukemia: a prospective comparison of interphase . fluorescence in situ hybridization and chromosome banding analysis . for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009. 114(24): p. 4939-4943.
74. Tokarski J.S., J.A. Newitt, C.Y.J. Chang, J.D. Cheng, M. Wittekind, S.E. Kiefer, K. Kish, F.Y.F. Lee, R. Borzillerri, L.J. Lombardo, D. Xie, Y. Zhang, and H.E. Klei, The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants. Cancer Research, 2006. 66(11): p. 5790-5797.
75. Wei G., S. Rafiyath, and D. Liu, First-line treatment.for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology & Oncology, 2010. 3(1): p. 47.